| Literature DB >> 29107183 |
Caitlin M O'Connor1, Abbey Perl1, Daniel Leonard2, Jaya Sangodkar3, Goutham Narla4.
Abstract
Protein phosphatase 2A (PP2A) is a major serine/threonine phosphatase that regulates many cellular processes. Given the central role of PP2A in regulating diverse biological functions and its dysregulation in many diseases, including cancer, PP2A directed therapeutics have become of great interest. The main approaches leveraged thus far can be categorized as follows: 1) inhibiting endogenous inhibitors of PP2A, 2) targeted disruption of post translational modifications on PP2A subunits, or 3) direct targeting of PP2A. Additional insight into the structural, molecular, and biological framework driving the efficacy of these therapeutic strategies will provide a foundation for the refinement and development of novel and clinically tractable PP2A targeted therapies.Entities:
Keywords: ABL-127; Bortezomib; CIP2A; Cancer; Celastrol; Cell signaling; Drug development; Erlotinib; FTY720; LB-100; LCMT-1; OP449; PME-1; PP2A; Phenothiazines; Protein phosphatase 2A; Protein phosphatases; SET; SMAPs; Tumor suppressors
Mesh：
Substances：
Year: 2017 PMID： 29107183 PMCID： PMC5927617 DOI： 10.1016/j.biocel.2017.10.008
Source DB: PubMed Journal: Int J Biochem Cell Biol ISSN： 1357-2725 Impact factor: 5.085